Patents by Inventor Eleonora Leucci

Eleonora Leucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UVEAL MELANOMA TREATMENT
    Publication number: 20220211726
    Abstract: The invention relates to antibiotics inhibiting the 30S ribosomal subunit, such as tigecycline, for use in the treatment of uveal melanoma.
    Type: Application
    Filed: April 2, 2020
    Publication date: July 7, 2022
    Inventors: Eleonora LEUCCI, Roberto VENDRAMIN
  • Inhibition of a lncRNA for treatment of melanoma
    Patent number: 9821004
    Abstract: This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: November 21, 2017
    Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, UNIVERSITEIT GENT
    Inventors: Jean-Christophe Marine, Eleonora Leucci, Joke Vandesompele, Pieter Mestdagh
  • INHIBITION OF A lncRNA FOR TREATMENT OF MELANOMA
    Publication number: 20160271163
    Abstract: This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.
    Type: Application
    Filed: August 20, 2014
    Publication date: September 22, 2016
    Inventors: Jean-Christophe Marine, Eleonora Leucci, Joke Vandesompele, Pieter Mestdagh
  • Inhibition of a lncRNA for treatment of melanoma
    Patent number: RE48801
    Abstract: This disclosure relates to the field of cancer, particularly the field of melanoma. It was found that a particular long non-coding RNA (lncRNA) is specifically up-regulated in melanoma (but not other tumor) cells as compared to melanocytes. Inhibition of this lncRNA in melanoma cells leads to induction of apoptosis and is a novel therapeutic strategy in the treatment of melanoma.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: November 2, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Universiteit Gent
    Inventors: Jean-Christophe Marine, Eleonora Leucci, Joke Vandesompele, Pieter Mestdagh